Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus

What Was Tested

In this phase 2, phase 3 trial, researchers set out to test Semaglutide.

It had 1 arm (groups): Semaglutide (experimental).

The registry classes the interventions as drug.

More on the Plan

A kidney transplant is the best treatment for people living with kidney failure as it allows people to live longer with a better quality of life.

However, one in four kidney transplant recipients will develop diabetes after transplant.

Kidney transplant recipients who get diabetes after transplant are up to three times more likely to have heart disease and die prematurely.

Semaglutide is a drug that is commonly used to treat diabetes and obesity.

Who Took Part

Enrollment: 37 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Signed and dated written informed consent. Adult (≥18 years) recipients of a living or deceased donor kidney transplant. Between 4- and 12-weeks post kidney transplant. At risk for PTDM at the time of transplant based on the following criteria:. BMI ≥ 25 kg/m2, or.

The full record lists 9 inclusion and 12 exclusion criteria; among the exclusions: kidney-pancreas transplant recipient; acute coronary syndrome, transient ischemic attack or stroke within 30 days prior to screening; history of pancreatitis.

How the Study Was Run

It was run as a single-group and open-label study.

Everyone knew when Semaglutide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2026-09-05 with completion listed for 2029-06-30.

It ran at 2 sites in Canada (2).

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: 2-hour OGTT (time frame: 24 weeks).

It also tracked 19 secondary outcomes, for example Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability], Estimated GFR, Change in fasting blood glucose, GFR, Change in serum insulin and Change in HbA1c.

What This Means in Plain Language

Put simply, this is a phase 2, phase 3 trial of Semaglutide in 37 people.

Its size is small, so on its own it can only give an early look.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.